Investor Alert

Associated Press Archives | Email alerts

April 12, 2021, 11:41 p.m. EDT

Australia has its second likely AstraZeneca vaccine blood-clot case

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC ADR (AZN)
  • X
    Pfizer Inc. (PFE)

or Cancel Already have a watchlist? Log In

By Associated Press

CANBERRA, Australia — Australian authorities have identified a second case of a rare blot clot likely linked to the AstraZeneca coronavirus vaccine.

Officials said Tuesday the woman is in her 40s and is in a stable condition. A 44-year-old man developed the same condition following an AstraZeneca /zigman2/quotes/200304487/composite AZN +0.62% injection March 22.

Australia has administered 700,000 doses of the AstraZeneca vaccine since early March. That equates to a clotting frequency of 1-in-350,000 cases. British authorities say the risk of such blood clots has been 1-in-250,000 in that country.

Australia had planned to rely on Australian-manufactured AstraZeneca for delivering at least one dose of a vaccine to all eligible adults among its population of 26 million by October. But it said last week the Pfizer /zigman2/quotes/202877789/composite PFE +1.00% vaccine is now the preferred option for people under 50 because of the potential risk from AstraZeneca.

US : U.S.: Nasdaq
$ 53.81
+0.33 +0.62%
Volume: 4.78M
May 7, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$141.94 billion
Rev. per Employee
$ 39.58
+0.39 +1.00%
Volume: 33.81M
May 7, 2021 4:02p
P/E Ratio
Dividend Yield
Market Cap
$220.78 billion
Rev. per Employee

Get news alerts on AstraZeneca PLC ADR — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.